Filana Therapeutics
FLNA
145 hedge funds and large institutions have $291M invested in Filana Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 58 increasing their positions, 28 reducing their positions, and 24 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 28
47% more call options, than puts
Call options by funds: $54.8M | Put options by funds: $37.2M
1.72% more ownership
Funds ownership: 26.96% → 28.68% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 153 → 145 (-8)
12% less capital invested
Capital invested by funds: $332M → $291M (-$41.4M)
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.48M |
| 2 |
SG Americas Securities
New York
|
+$3.98M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.26M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.94M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$3.45M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$2.9M |
| 3 |
Goldman Sachs
New York
|
-$2.65M |
| 4 |
SC
Sculptor Capital
New York
|
-$2.11M |
| 5 |
Morgan Stanley
New York
|
-$1.74M |
FLNA Hedge Fund Activity: Q1 2023 in Review
145 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2023, worth a combined $291M — down 12% from $332M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of FLNA and 17 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 58 added.
The largest buyer was Susquehanna International Group, adding an estimated $4.48M. The largest seller was Invesco, cutting an estimated $3.45M.
- 145 institutional investors held Filana Therapeutics (FLNA) as of Q1 2023, down from 153 in Q4 2022.
- Funds reported $291M of Filana Therapeutics stock for Q1 2023, down 12% quarter-over-quarter.
- 17 funds opened new Filana Therapeutics positions in Q1 2023 and 24 closed out, a net change of -7 holders.
- The largest Filana Therapeutics buyer in Q1 2023 was Susquehanna International Group, an estimated $4.48M added.
- The largest Filana Therapeutics seller in Q1 2023 was Invesco, an estimated $3.45M sold.
Based on aggregated 13F filings for Q1 2023.